New Approach to Glioblastoma Treatment Addressing the Critical Unmet Medical Need.
Overview
Berubicin is an exciting new drug that is one of the first anthracyclines proven to cross the blood-brain barrier (BBB) and able to reach brain tumors. This discovery can potentially extend the clinical use of anthracyclines to brain tumors, specifically GBM.
For more information about the drug, please visit ClinicalTrials.gov.
Clinic Development
Berubicin’s Phase I clinical trial, the first time it was tested in humans, yielded very promising results with 44% of the patients showing a clinical response. In addition, Berubicin has shown evidence of improved overall survival in a patient population that currently has a dismal median survival rate of only 14.6 months from diagnosis.
Grants / Funding
This project is co-financed by the European Union from the European Regional Development Fund under the Smart Growth Operational Program 2014-2020, Sectoral Programme InnoNeuroPharm, Priority Axis I: Support R&D carried out by enterprises, Measure 1.2: Sectoral R&D Programmes, implemented under National Center for Research and Development.
Co-financing of the project from the EU: 22 033 066,00 PLN
Total Project value: PLN 33 306 215,00
Contribution of the European Union Funds: PLN 22 033 066,00
Regulatory
Berubicin has previously received an Orphan Drug designation in the US, which provides seven years of marketing exclusivity.
Partners, Affiliations & License
Reata Pharmaceuticals (Nasdaq: RETA) - $3 Billion- dollar Nasdaq listed company
Houston Pharmaceuticals
CNS Pharmaceuticals – co-development partner
WPD owns the exclusive license to 30 countries in Europe and Asia and also Poland and Russia.
This project is co-financed by the European Union from the European Regional Development Fund under the Smart Growth Operational Program 2014-2020, Sectoral Programme InnoNeuroPharm, Priority Axis I: Support R&D carried out by enterprises, Measure 1.2: Sectoral R&D Programmes, implemented under National Center for Research and Development.
Co-financing of the project from the EU: 22 033 066,00 PLN